A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Patients with Advanced Cancer
A Study in Subjects With Advanced Cancer
Sponsor: Agenus Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS7014
U.S. Govt. ID: NCT04121676
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body's immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in animals. This is the first time that the Study Drug will be given to humans. The study will also evaluate how the body breaks down the study drug (pharmacokinetics or PK) and what is the effect of the study drug on the body (pharmacodynamics). In addition, the study will investigate the potential effectiveness of the study drug and if your body is producing certain substances (known as antibodies) against the study drug (anti-drug antibodies). It will also study certain proteins that give more information about the disease and/or the body's response to the disease. These specific proteins are known as biomarkers. Cancers include: Bladder cancer, breast cancer, colon and rectal cancer, cervical cancer, ovarian cancer, kidney/adrenal cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Is your life expectancy 3 months or greater? Yes No
Do you have a confirmed diagnosis of metastatic or advanced cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162